Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JUUAP
ADC Name
EphA2-targeted mAb ADC 19
Synonyms
EphA2-targeted-mAb-ADC-19
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Investigative
Indication
In total 4 Indication(s)
Acute monocytic leukaemia [ICD11:2A60]
Investigative
Acute myeloid leukaemia [ICD11:2A60]
Investigative
Anaplastic large cell lymphoma [ICD11:2A90]
Investigative
Hodgkin lymphoma [ICD11:2B30]
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
Anti-EPHA2 mAb
  Antibody Info 
Antigen Name
Ephrin type-A receptor 2 (EPHA2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
EphA2-targeted mAb ADC 19 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
7.3
nM
THP1-Dual cells
Childhood acute monocytic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 7.30 nM Positive EPHA2 expression (EPHA2+++/++)
Method Description
Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model Childhood acute monocytic leukemia THP1-Dual cells CVCL_X599
References
Ref 1 Immunomodulatory antibody-drug conjugates; 2022-07-21.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.